Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.46 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.43 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26847324 | 0.82 | PIK3CD (0.43) | CYP3A4CYP2C19AOC3PDE10A | |
| SCHEMBL26848733 | 0.79 | PIK3CA (0.45) | AOC3 | |
| SCHEMBL2095368 | 0.78 | APP (0.51) | AOC3 | |
| SCHEMBL4138997 | 0.74 | KDM4E (0.58) | AOC3MAPT | |
| SCHEMBL13047620 | 0.72 | ABL1 (0.41) | CYP2A6CYP2B6CYP3A4CYP2C19CHRM4 | |
| SCHEMBL13047767 | 0.72 | CYP3A4 (0.38) | CYP2A6CYP2B6CYP3A4CYP2C19CHRM4 | |
| SCHEMBL2094527 | 0.72 | DCK (0.53) | — | |
| SCHEMBL13680530 | 0.72 | CYP2A6 (0.54) | CYP2A6CYP2B6CYP3A4CYP2C19AOC3 | |
| SCHEMBL10162540 | 0.72 | CYP2A6 (0.53) | CYP2A6CYP2B6CYP3A4CYP2C19CYP2E1 | |
| SCHEMBL12641895 | 0.71 | APP (0.51) | AOC3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | SPPL2A, SPPL2B, BACE1 | CYP2A6 3043/4885CYP2B6 3614/4885CYP3A4 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.